T
Terra L. Lasho
Researcher at Mayo Clinic
Publications - 349
Citations - 20094
Terra L. Lasho is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Myelofibrosis & Chronic myelomonocytic leukemia. The author has an hindex of 71, co-authored 318 publications receiving 17476 citations. Previous affiliations of Terra L. Lasho include Geron Corporation & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Animesh Pardanani,Ross L. Levine,Terra L. Lasho,Yana Pikman,Ruben A. Mesa,Martha Wadleigh,David P. Steensma,Michelle A. Elliott,Alexandra P. Wolanskyj,William J. Hogan,Rebecca F. McClure,Mark R. Litzow,D. Gary Gilliland,Ayalew Tefferi +13 more
TL;DR: In this paper, a gain-of-function MPL mutation, MPLW515L, was described in patients with JAK2V617F-negative myelofibrosis with myeloid metaplasia (MMM).
Journal ArticleDOI
Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis
Ayalew Tefferi,Paola Guglielmelli,Dirk R. Larson,Christy Finke,Emnet A. Wassie,Lisa Pieri,Naseema Gangat,Rajmonda Fjerza,Alem A. Belachew,Terra L. Lasho,Rhett P. Ketterling,Curtis A. Hanson,Alessandro Rambaldi,Guido Finazzi,Juergen Thiele,Tiziano Barbui,Animesh Pardanani,Alessandro M. Vannucchi +17 more
TL;DR: It is concluded that life expectancy in morphologically defined ET is significantly reduced but remains superior to that of PV, regardless of mutational status, and in PMF, JAK2/CALR/MPLmutational status is prognostically informative.
Journal ArticleDOI
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi,Rakhee Vaidya,Rakhee Vaidya,Domenica Caramazza,Domenica Caramazza,Christy Finke,Christy Finke,Terra L. Lasho,Terra L. Lasho,Animesh Pardanani +9 more
TL;DR: The presence of specific cytokine-phenotype associations in PMF and a prognostically relevant plasma cytokine signature that might prove useful as a laboratory tool for predicting and monitoring treatment response are marked.
Journal ArticleDOI
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
David P. Steensma,David P. Steensma,Gordon W. Dewald,Gordon W. Dewald,Terra L. Lasho,Terra L. Lasho,Heather Powell,Heather Powell,Rebecca F. McClure,Rebecca F. McClure,Ross L. Levine,Ross L. Levine,D. Gary Gilliland,D. Gary Gilliland,Ayalew Tefferi,Ayalew Tefferi +15 more
TL;DR: The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders.
Journal ArticleDOI
CALR vs JAK2 vs MPL -mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A Tefferi,Terra L. Lasho,Christy Finke,Ryan A. Knudson,Rhett P. Ketterling,C H Hanson,Margherita Maffioli,Domenica Caramazza,Francesco Passamonti,Animesh Pardanani +9 more
TL;DR: ‘CALR–ASXL1+’ and ‘triple-negative’ are identified as high-risk molecular signatures in PMF.